Artelo Biosciences
ARTL
4 hedge funds and large institutions have $245K invested in Artelo Biosciences in 2020 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
300% more funds holding
Funds holding: 1 → 4 (+3)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
+$159K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$38.7K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$7.91K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$7.57K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KC
1
Kepos Capital
New York
| $183K | +$159K | +926 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $44K | +$38.7K | +225 | New |
|
|
CS
3
Credit Suisse
Zurich,
Switzerland
| $9K | +$7.57K | +44 | New |
|
|
4
Northern Trust
Chicago,
Illinois
| $9K | +$7.91K | +46 | New |
|
ARTL Hedge Fund Activity: Q4 2020 in Review
4 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q4 2020, worth a combined $245K.
Buyers outnumbered sellers: 4 funds opened new ARTL positions and 1 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Kepos Capital, opening a new position worth an estimated $159K.
- 4 institutional investors held Artelo Biosciences (ARTL) as of Q4 2020, up from 1 in Q3 2020.
- Funds reported $245K of Artelo Biosciences stock for Q4 2020.
- 4 funds opened new Artelo Biosciences positions in Q4 2020 and 1 closed out, a net change of +3 holders.
- The largest Artelo Biosciences buyer in Q4 2020 was Kepos Capital, an estimated $159K added.
Based on aggregated 13F filings for Q4 2020.